Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Summary
Neoadjuvant immunochemotherapy can effectively increase the postoperative pathological complete response rate, improve the survival rate of patients, and reduce the risk of recurrence in oral squamous cell carcinoma (OSCC). Programmed death ligand-1 (PD-L1) plays a role in inhibiting the cancer-immune cycle by binding to negative regulatory factors of T cell activation such as PD-1 and B7.1. It has achieved good therapeutic effects in lung cancer, liver cancer and other cancers. Previous studies have shown that three cycles of PD-L1 inhibitors combined with chemotherapy have satisfactory efficacy and safety in locally advanced oral squamous cell carcinoma. However, during the three-cycle treatment process, due to the accumulation of drug toxicity, patients' tolerance to adverse reactions decreases, increasing the risk of serious adverse events and psychological pressure on patients. Based on this, this study aims to explore the efficacy of two cycles of avelumab (PD-L1 inhibitor) combined with chemotherapy in locally advanced oral squamous cell carcinoma, to explore whether it can achieve the same efficacy as three cycles while shortening the treatment time, reduce the risk of serious adverse events, and further verify the efficacy and safety of PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced oral squamous cell carcinoma. This study uses the postoperative pathological complete response (PCR) rate as the primary outcome indicator, and the objective response rate (ORR), major pathological response (MPR) rate, 2-year disease-free survival (EFS) rate, and 2-year and 5-year overall survival (OS) rate as secondary outcome indicators to evaluate the efficacy and long-term survival impact.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2025-08-15
Completion Date
2027-12-31
Last Updated
2025-08-22
Healthy Volunteers
No
Interventions
Preoperative neoadjuvant immunotherapy chemotherapy
Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adalimumab 1200mg are administered intravenously. According to the allocation to the short-course group or long-course group, two or three cycles are carried out respectively, and surgery is performed 21 days after the end of the last cycle of medication. Post-surgery, radiotherapy and chemotherapy are administered based on the pathological stage. Patients who do not require radiotherapy receive maintenance therapy with PD-L1 inhibitor (adalimumab) alone. Patients who require radiotherapy and chemotherapy receive maintenance therapy with the drug alone at the same time. The duration of medication for all patients is one year (calculated from the time of the first medication at the initial diagnosis to the last medication after the surgery).
Two courses of preoperative neoadjuvant immunotherapy chemotherapy
Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg were administered intravenously. Two treatment courses were carried out in total, and surgery was performed 21 days after the end of the second course of medication. Postoperative radiotherapy and chemotherapy were administered based on the pathological stage. Patients who did not require radiotherapy received adebrelimab (PD-L1 inhibitor) monotherapy maintenance. Patients who required radiotherapy and chemotherapy received monotherapy maintenance during the same period. The duration of medication for all patients was one year (from the first medication time at the initial diagnosis to the last medication time after surgery).
Three courses of preoperative neoadjuvant immunotherapy chemotherapy
Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg are administered intravenously. This treatment is carried out for a total of three cycles, and surgery is performed 21 days after the end of the third cycle. Post-surgery, radiotherapy and chemotherapy are administered based on the pathological stage. Patients who do not require radiotherapy receive adebrelimab (PD-L1 inhibitor) monotherapy maintenance. Patients who require radiotherapy and chemotherapy receive monotherapy maintenance simultaneously. The duration of medication for all patients is one year (from the first administration after diagnosis to the last administration after surgery).